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1. INTRODUCTION 
 
FLOATING DRUG DELIVERY SYSTEM 
The oral route is considered as the most promising safe and effective route of drug 
delivery. Effective oral drug delivery may depend upon the factors such as gastric 
emptying process, gastrointestinal transit time of dosage form, drug release from the 
dosage form and site of absorption of drugs.1  
Most of the oral dosage forms possess several physiological limitations such as 
variable gastrointestinal transit, because of variable gastric emptying leading to non-
uniform absorption profiles, incomplete drug release and shorter residence time of the 
dosage form in the stomach.2 This leads to incomplete absorption of drugs having 
absorption window especially in the upper part of the small intestine, as once the drug 
passes down the absorption site, the remaining quantity goes unabsorbed. The gastric 
emptying of dosage forms in humans is affected by several factors because of which wide 
inter- and intra-subject variations are observed. Since many drugs are well absorbed in the 
upper part of the gastrointestinal tract, such high variability may lead to non-uniform 
absorption and makes the bioavailability unpredictable. Hence a beneficial delivery system 
would be one which possesses the ability to control and prolong the gastric emptying time 
and can deliver drugs in higher concentrations to the absorption site (i.e. upper part of the 
small intestine).3 
Currently, a number of FDDS involving various technologies, carrying their own 
advantages and limitations were developed such as, single and multiple unit hydro 
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dynamically balanced systems (HBS), single and multiple unit gas generating systems, 
hollow microspheres and raft forming systems.4 
FDDS is a formulation of a drug with gel forming hydrocolloids meant to remain 
buoyant in the stomach contents. Drug dissolution and release from the dosage form 
retained in the stomach fluids occur at the pH of the stomach under fairly controlled 
conditions. The retentive characteristics of the dosage form are not significant for the drugs 
that5 
 are insoluble in intestinal fluids 
 act locally 
 exhibit site-specific absorption. 
 
Criteria for HBS 6,7,8 
 Must have sufficient structure to form a cohesive gel barrier.  Effective oral drug 
delivery may depend upon the factors such as gastric emptying process, 
gastrointestinal transit time of dosage form, drug release from the dosage form 
and site of absorption of drugs 
 Must maintain an overall specific gravity less than that of gastric content. 
 Should dissolve slowly enough to serve as a reservoir for the delivery system. 
 
Floating systems are one of the important categories of drug delivery systems with 
gastric retentive behavior. Drugs that could take advantage of gastric retention 
include furosemide, cyclosporine, allopurinol ciprofloxacin and metformin. Drugs whose 
solubility is less in the higher pH of the small intestine than the stomach (e.g. 
chlordiazepoxide and cinnarizine, the drugs prone for degradation in the intestinal pH (e.g. 
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captopril), and the drugs for local action in the stomach (e.g. misoprostol) can be delivered 
in the form of dosage forms with gastric retention. Antibiotics, catecholamines, sedative, 
analgesics, anticonvulsants, muscle relaxants, antihypertensive and vitamins can be 
administered in HBS dosage form. 
 
Controlled release or Extended-release dosage forms with prolonged residence times in the 
stomach are highly desirable for drugs which are 
 Administered two or more time a day 
 Only absorbed in the upper GI regions 
 Insoluble in water 
 Targeted at sites in the upper GI tract 
 Bioavailable through active transport mechanisms 
 Irritating to the mucosa 
 Unbalancing, irritating, or unsafe in the lower GI region  
 More effective when plasma levels are more constant 
 That are locally active in the stomach, that are locally active in the stomach 
 That has an absorption window in the stomach or in the upper small intestine 
 That are unstable in the intestinal or colonic environment 
 Have low solubility at high pH values 
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PHYSIOLOGY OF STOMACH 
The GI tract is essentially a tube about nine meters long that runs through the 
middle of the body from the mouth to the anus and includes the throat (pharynx). 
Oesophagus, stomach, small intestine (consisting of the duodenum, jejunum and ileum) and 
large intestine (consisting of cecum, appendix, colon and rectum).9 The wall of the GI tract 
has the same general structure throughout most of its length from the oesophagus to the 
anus, with some local variations for each region. The stomach is an organ with a capacity 
for storage and mixing. The antrum region is responsible for mixing and grinding of gastric 
contents. Under fasting conditions, the stomach is a collapsed bag with a residual volume 
of approximately 50 ml and contains a small amount of gastric fluid (pH 1-3) and air. The 
mucus spread and covers the mucosal surface of the stomach as well as the rest of the GI 
tract. The GI tract is in a state of continuous motility consisting of two modes: 
interdigestive motility pattern and digestive motility pattern. The former is dominant in the 
fasted state with a prominary function of cleaning up the residual content of the upper GI 
tract. The average length of the stomach is about 0.2 meters and the apparent absorbing 
surface area is about 0.1 m2. 
                               
Figure 1  Anatomy of stomach. 
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Table 1  Anatomy and Physiology of GIT 10,11 
Section Average 
length (cm) 
Villi 
present 
Absorption 
mechanism 
pH Major              constituents TT of food (hr) 
Oral cavity 15-20 
 
- Passive diffusion, 
convective transport 
5.2-6.8 Amylase, maltase, ptyalin, 
mucins 
short 
Esophagus 25 - - 5-6 - Very short 
Stomach 20 - Passivediffusion, 
convective transport 
1.2-3.5 HCl, pepsin, rennin, lipase, 
intrinsic  
0.25-3.00 
Duodenum 25 + Passive diffusion, 
convective transport, 
active transport,     
facilitated transport, 
ion pair pinocytosis 
4.6-6.0 Bile, trypsin, chymotripsin, 
amylase, maltase, lipase, 
nuclease, CYP3A5 
1-2 
Jejunum 300 ++ Passivediffusion, 
convectivetransport, 
active transport, 
facilitated transport 
6.3-7.3 Amylase, maltase, lactase, 
sucrase, CYP3A5 
- 
Colon 150 - Passive diffusion, 
convective transport 
7.9-8.0 - 4-20 
Rectum 15-19 - Passive diffusion, 
convective transport, 
pinocytosis 
7.5-8.0 - Variable 
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GASTRIC pH 
The gastric pH is not constant rather it is influenced by various factors such as diet, 
disease, presence of gases, fatty acids and other fermentation products, however the reported 
mean value of gastric pH in fasted healthy subjects is 1.1±0.5 and in fed state basal gastric 
secretion in women is slightly lower than that of men . The pH in the proximal duodenum 
may rise as high as 4 pH units from the stomach. This increase in pH caused by the 
bicarbonate secreted by the pancreas and the duodenal mucosa that neutralize acidic chime 
peristalses from the stomach. The mean pH value in fasted duodenum has been reported to be 
5.8±0.3 in healthy subjects while the fasted small intestine has been observed to have a mean 
pH of 6.0±0.14. Passing from jejunum through the mid small intestine and ileum, pH rises 
from about 6.6 to 7.5.12 
Gastric pH is an important consideration in selecting a drug substance, excipients and drug 
carrier(s) for designing intra gastric delivery systems. 
 
GASTRIC MOTILITY AND TRANSIT TIME 
The GI tract is always in a state of continuous motility. There are two modes of 
motility pattern the digestive mode and inter digestive mode. In case of fasted state an inter 
digestive series of electrical events occurs in cyclic manner both through stomach and small 
intestine every 2-3 hr. This electrical activity is termed as inter digestive myo electric cycle or 
migrating myo electric complex (MMC), which is further divided into four phases.13 
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Table 2 Phases of myoelectric complex 
Phase I Period of no contraction. 
Phase II Period of intermittent contraction. 
Phase III Period of regular contractions at maximal frequency that migrate distally. 
Phase IV Period of transition between phase III and phase I. 
 
FACTORS AFFECTING THE GASTRORETENTIVE SYSTEM 
Various attempts have been made to retain the dosage form in the stomach as a way of 
increasing the retention time. These attempts include use of floating dosage forms (gas-
generating systems and swelling or expanding systems), mucoadhesive systems, high-density 
systems, modified shape systems, gastric-emptying delaying devices and co-administration of 
gastric-emptying delaying drugs. Most of these approaches are influenced by a number of 
factors that affect their bioavailability and efficacy of the gastro retentive system.14 
 Density – Gastric retention time (GRT) is a function of dosage form buoyancy that is 
dependent on the density. 
 Size – Dosage form units with a diameter of more than 7.5 mm are reported to have 
an increased GRT compared with those with a diameter of 9.9 mm. 
 Shape of dosage form – Tetrahedron and ring shaped devices with a flexural 
modulus of 48 and 22.5 kilo pounds per square inch (KSI) are reported to have better 
GRT 90% to 100% retention at 24 hours compared with other shapes. 
 Single or multiple unit formulation – Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to failure of 
units, allow co-administration of units with different release profiles or containing 
incompatible substances and permit a larger margin of safety against dosage form 
failure compared with single unit dosage forms. 
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 Fed or unfed state – Under fasting conditions, the GI motility is characterized by 
periods of strong motor activity or the migrating myoelectric complex (MMC) that 
occurs every 1.5 to 2 hours. The MMC sweeps undigested material from the stomach 
and, if the timing of administration of the formulation coincides with that of the 
MMC, the GRT of the unit can be expected to be very short. However, in the fed 
state, MMC is delayed and GRT is considerably longer. 
 Caloric content – GRT can be increased by 4 to10 hours with a meal that is high in 
proteins and fats. 
 Frequency of feed – The GRT can increase by over 400 minutes when successive 
meals are given compared with a single meal due to the low frequency of MMC. 
 Gender – Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with their 
age and race matched female counterparts (4.6±1.2 hours), regardless of the weight, 
height and body surface. 
 Age – Elderly people, especially those over 70, have a significantly longer GRT. 
 Posture – GRT can vary between supine and upright ambulatory states of the patient. 
 Concomitant drug administration – Anticholinergics like atropine and 
propantheline, opiates like codeine and prokinetic agents like metoclopramide and 
cisapride can affect floating time. 
 Biological factors – Diabetes and Crohn’s disease, etc. 
ADVANTAGES OF GASTRORETENTIVE DRUG DELIVERY SYSTEM15,16 
      Gastroretentive drug delivery systems have numerous advantages listed below 
 The principle of HBS can be used for any particular medicament or class of 
medicament. 
 The HBS formulations are not restricted to medicaments, which are principally 
absorbed from the stomach. Since it has been found that these are equally efficacious 
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with medicaments which are absorbed from the intestine e.g. Chlorpheniramine 
maleate. 
 The HBS are advantageous for drugs absorbed through the stomach e.g. ferrous salts 
and for drugs meant for local action in the stomach and treatment of peptic ulcer 
disease e.g. antacids. 
 The efficacy of the medicaments administered utilizing the sustained release principle 
of HBS has been found to be independent of the site of absorption of the particular 
medicaments. 
 Administration of a prolonged release floating dosage form tablet or capsule will 
result in dissolution of the drug in gastric fluid. After emptying of the stomach 
contents, the dissolved drug available for absorption in the small intestine. It is 
therefore expected that a drug will be fully absorbed from the floating dosage form if 
it remains in solution form even at alkaline pH of the intestine. 
 When there is vigorous intestinal movement and a short transit time as might occur in 
certain type of diarrhoea, poor absorption is expected under such circumstances it 
may be advantageous to keep the drug in floating condition in stomach to get a 
relatively better response. 
 Gastric retention will provide advantages such as the delivery of drugs with narrow 
absorption windows in the small intestinal region. 
 Many drugs categorized as once-a-day delivery have been demonstrated to have sub 
optimal absorption due to dependence on the transit time of the dosage form, making 
traditional extended release development challenging. Therefore, a system designed 
for longer gastric retention will extend the time within which drug absorption can 
occur in the small intestine. 
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DISADVANTAGES OF GASTRORETENTIVE DRUG DELIVERY SYSTEM17,18 
 There are certain situations where gastric retention is not desirable. Aspirin and non-
steroidal anti-inflammatory drugs are known to cause gastric lesions and slow release 
of such drugs in the stomach is unwanted. 
 Thus, drugs that may irritate the stomach lining or are unstable in its acidic 
environment should not be formulated in gastroretentive systems. 
 Furthermore, other drugs, such as isosorbide dinitrate, that are absorbed equally well 
throughout the GI tract will not benefit from incorporation into a gastric retention 
system . 
 Gastric retention is influenced by many factors such as gastric motility, pH and 
presence of food. These factors are never constant and hence the buoyancy cannot be 
predicted exactly or accurately. 
 Gastric emptying of floating forms in supine subjects may occur at random and 
become highly dependent on the diameter. Therefore, patients should not be dosed 
with floating forms just before going to bed. 
 High variability in gastric emptying time due to variations in emptying process. 
 Unpredictable bioavailability. 
 
FLOATING DRUG DELIVERY SYSTEMS 
The concept of FDDS was described in the literature as early as 1962. FDDS have a 
bulk density less than gastric fluids and so remain buoyant in the stomach without affecting 
the gastric emptying rate for a prolonged period of time. While the system is floating on the 
gastric contents the drug is released slowly at the desired rate from the system. This results in 
an increased GRT and a better control of fluctuations in plasma drug concentration.19 
11 
 
             
Fig 2 Mechanism of floating system 
 
Fig 3. Intragastric residence positions of floating and nonfloating units. 
Formulation of this device must comply with the following criteria 
 It must have sufficient structure to form a cohesive get barrier. 
 It must maintain an overall specific gravity lower than that of gastric contents (1.004-
1.010). 
 It should dissolve slowly enough to serve as a drug reservoir. 
Types of floating drug delivery systems 
Based on the mechanism of buoyancy and two distinctly different technologies have 
been utilized in the development of FDDS. 
1) Non- Effervescent FDDS 
2) Effervescent FDDS 
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1) Non-Effervescent FDDS 
The Non-effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
hydrophilic gums, polysaccharides and matrix forming materials such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as well as bioadhesive polymers such as 
Chitosan and carbopol.20,21 
Working Principle of Non- Effervescent-Type of FDDS 
Capsule/tablet contains a mixture of drug and hydrocolloids. Upon contact with 
gastric fluid, the mixture swells and forms a gelatinous barrier thereby remaining buoyant in 
the gastric juice for an extended period of time. 
 
Fig 4 Working principle of non-effervescent type of FDDS. 
The various types of this system are as: 
A. Single Layer Floating Tablets 
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, 
which swells in contact with gastric fluid and maintains bulk density of less than unity. 
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They are formulated by intimate mixing of drug with low-density enteric materials 
such as CAP, HPMC. 
B. Bi-layer Floating Tablets 
A bi-layer tablet contain two layer one immediate release layer which releases initial 
dose from system while the another sustained release layer absorbs gastric fluid, forming an 
impermeable colloidal gel barrier on its surface, and maintain a bulk density of less than unity 
and thereby it remains buoyant in the stomach.22 
 
C.  Alginate Beads 
Multi-unit floating dosage forms were developed from freeze-dried calcium alginate. 
Spherical beads of approximately 2.5 mm diameter can be prepared by dropping sodium 
alginate solution into aqueous solution of calcium chloride, causing precipitation of calcium 
alginate leading to formation of porous system, which can maintain a floating force for over 
12 hours. When compared with solid beads, which gave a short residence time of 1 hour, and 
these floating beads gave a prolonged residence time of more than 5.5 hours.23 
D.  Hollow Microspheres 
Hollow microspheres (microballoons), loaded with drug in their outer polymer shells 
are prepared by a novel emulsion-solvent diffusion method. The ethanol: dichloromethane 
solution of the drug and an enteric acrylic polymer is poured into an agitated aqueous 
solution of PVA that is thermally controlled at 400C. The gas phase generated in dispersed 
polymer droplet by evaporation of dichloromethane forms an internal cavity in microsphere 
of polymer with drug. The microballoons float continuously over the surface of acidic 
dissolution media containing surfactant for more than 12 hours in vitro.24 
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2) Effervescent System 
Effervescent systems include use of gas generating agents, carbonates (ex. Sodium 
bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present in the 
formulation to produce carbon dioxide (CO2) gas, thus reducing the density of the system and 
making it float on the gastric fluid. An alternative is the incorporation of matrix containing 
portion of liquid, which produce gas that evaporates at body temperature. 
These effervescent systems further classified into two types. 
1. Gas generating systems 
2. Volatile Liquid/Vacuum Containing Systems 
1. Gas Generating Systems 
A. Tablets 
Floating bilayer tablets with controlled release for furosemide were developed by 
Ozdemir et al., 2000. The low solubility of the drug could be enhanced by using the kneading 
method, preparing a solid dispersion with β cyclodextrin mixed in a 1:1 ratio (Singh and 
Brahma, 2000). One layer contained the polymers HPMC K4M, HPMC K100M and CMC 
(for the control of the drug delivery) and the drug. The second layer contained the 
effervescent mixture of sodium bicarbonate and citric acid. The in vitro floating studies 
revealed that the lesser the compression force the shorter is the time of onset of floating, i.e., 
when the tablets were compressed at 15 MPa, these could begin to float at 20 minutes 
whereas at a force of 32 MPa the time was prolonged to 45 minutes. Radiographic studies on 
6 healthy male volunteers revealed that floating tablets were retained in stomach for 6 hours 
and further blood analysis studies showed that bioavailability of these tablets was 1.8 times 
that of the conventional tablets. On measuring the volume of urine the peak diuretic effect 
seen in the conventional tablets was decreased and prolonged in the case of floating dosage 
form.  
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Developed a swellable asymmetric triple-layer tablet with floating ability to prolong 
the gastric residence time of triple drug regimen (tetracycline, metronidazole, and 
clarithromycin) in Helicobacter pylori–associated peptic ulcers using hydroxypropylmethyl 
cellulose (HPMC) and polyethylene oxide (PEO) as the rate-controlling polymeric membrane 
excipients. The design of the delivery system was based on the swellable asymmetric triple-
layer tablet approach. Hydroxypropylmethylcellulose and polyethylene oxide were the major 
rate-controlling polymeric excipients. Tetracycline and metronidazole were incorporated into 
the core layer of the triple-layer matrix for controlled delivery, while bismuth salt was 
included in one of the outer layers for instant release. The floatation was accomplished by 
incorporating a gas-generating layer consisting of sodium bicarbonate: calcium carbonate 
(1:2 ratios) along with the polymers. The in vitro results revealed that the sustained delivery 
of tetracycline and metronidazole over 6 to 8 hours could be achieved while the tablet 
remained afloat. The floating feature aided in prolonging the gastric residence time of this 
system to maintain high localized concentration of tetracycline and metronidazole.25 
                          
Fig 5  (A) Initial configuration of triple-layer tablet. (B) On contact with the dissolution medium the 
bismuth layer rapidly dissolves and matrix starts swelling. (C) Tablet swells and erodes. (D) And (E) 
Tablet erodes completely. 
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B. Floating capsules 
Floating capsules are prepared by filling with a mixture of sodium alginate and 
sodium bicarbonate. The systems were shown to float during in vitro tests as a result of the 
generation of CO2 that was trapped in the hydrating gel network on exposure to an acidic 
environment.26 
C. Multiple unit type floating pills 
The system consists of sustained release pills as ‘seeds’ surrounded by double layers. 
The inner layer consists of effervescent agents while the outer layer is of swellable membrane 
layer. When the system is immersed in dissolution medium at body temp, it sinks at once and 
then forms swollen pills like balloons, which float as they have lower density. This lower 
density is due to generation and entrapment of CO2 within the system.
27 
                      
                      
Fig 6 (a) A multi-unit oral floating dosage system. (b) Stages of floating mechanism: (A) penetration of 
water; (B) generation of CO2 and floating; (C) dissolution of drug. Key: (a) conventional SR pills; (b) 
effervescent layer; (c) swellable layer; (d) expanded swellable membrane layer; (e) surface of water in the 
beaker (370C). 
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D. Floating system with Ion-Exchange resins 
A floating system using ion exchange resin that was loaded with bicarbonate by 
mixing the beads with 1M sodium bicarbonate solution. The loaded beads were then 
surrounded by a semipermeable membrane to avoid sudden loss of CO2. Upon coming in 
contact with gastric contents an exchange of chloride and bicarbonate ions took place that 
resulted in CO2 generation thereby carrying beads toward the top of gastric contents and 
producing a floating layer of resin beads. The in vivo behavior of the coated and uncoated 
beads was monitored using a single channel analyzing study in 12 healthy human volunteers 
by gamma radio scintigraphy. Studies showed that the gastric residence time was prolonged 
considerably (24 hours) compared with uncoated beads (1 to 3 hours).28 
                             
Fig 7  Pictorial presentation of working of effervescent floating drug delivery system based on ion 
exchange resin. 
2. Volatile Liquid / Vacuum Containing Systems 
A. Intra-gastric floating gastrointestinal drug delivery system 
These systems can be made to float in the stomach because of floatation chamber, 
which may be a vacuum or filled with air or a harmless gas, while drug reservoir is 
encapsulated inside a micro-porous compartment. 
18 
 
               
Fig 8 Intra gastric floating gastrointestinal drug delivery device. 
B. Inflatable gastrointestinal delivery systems 
In these systems an inflatable chamber is incorporated, which contains liquid ether 
that gasifies at body temperature to cause the chamber to inflate in the stomach. These 
systems are fabricated by loading the inflatable chamber with a drug reservoir, which can be 
a drug impregnated polymeric matrix, encapsulated in a gelatin capsule. After oral 
administration, the capsule dissolves to release the drug reservoir together with the inflatable 
chamber. The inflatable chamber automatically inflates and retains the drug reservoir 
compartment in the stomach. The drug continuously released from the reservoir into the 
gastric fluid.29 
 
Fig 9  Inflatable gastrointestinal delivery system. 
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C. Intragastric osmotically controlled drug delivery system 
It is comprised of an osmotic pressure controlled drug delivery device and an inflatable floating 
support in a biodegradable capsule. In the stomach, the capsule quickly disintegrates to release the 
intra-gastric osmotically controlled drug delivery device. The inflatable support inside forms a 
deformable hollow polymeric bag that contains a liquid that gasifies at body temperature to inflate 
the bag. The osmotic pressure controlled drug delivery device consists of two components; drug 
reservoir compartment and an osmotically active compartment. The drug reservoir compartment is 
enclosed by a pressure responsive collapsible bag, which is impermeable to vapour and liquid and 
has a drug delivery orifice. The osmotically active compartment contains an osmotically active salt 
and is enclosed within a semipermeable housing. In the stomach, the water in the GI fluid is 
continuously absorbed through the semipermeable membrane into osmotically active compartment 
to dissolve the osmotically active salt. The osmotic pressure thus created acts on the collapsible bag 
and in turn forces the drug reservoir compartment to reduce its volume and activate drug release 
through the delivery orifice. The floating support is also made to contain a bioerodible plug that 
erodes after a predetermined time to deflate the support. The deflated drug delivery system is then 
emptied from the stomach.30 
 
Fig 10  Intragastric osmotically controlled drug delivery system 
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Bioadhesive drug delivery system 
Bioadhesion/Mucoadhesion for oral drug delivery 
The term bioadhesion is defined as adhesion to biological surface i.e. mucus and/or 
mucosal surface. In instances when the polymeric system interacts with mucus layer only, it 
is referred as mucoadhesion. In order to develop an ideal oral bioadhesive system, it is 
important to have a thorough understanding of mucosa, bioadhesive polymers and mucin-
polymer interactions in the physiological environment. 
Intestinal mucosa is composed of high molecular weight glycoproteins hydrated and 
covering the mucosa with a continuous adherent blanket. Mucin glycoproteins are rich with 
fucose and sialic acid groups at the terminal ends which provide a net negative charge in the 
acidic environment. The thickness of the mucin gel layer varies in different regions of the 
GIT with thickness ranging between 50-500 μm in stomach to 15-150μm in the colon. 
Cohesion of the mucin gel is dependent upon the glycoprotein concentration. The mucus 
layer is created biologically to play a number of important functions of protecting the 
underlying tissues from various diffusing/corrosive elements such as enzymes, acid and other 
toxic molecules. Also being a visco-elastic gel, it helps in the passage of food over the 
epithelium, thereby minimizing potential erosive damages. The mucus layer, in addition to 
providing protection, provides a barrier to drug absorption.31 
Various investigators have proposed different mucin-polymer interactions, such as 
 Wetting and swelling of the polymer to permit intimate contact with the biological 
tissue 
 Interpenetration of bioadhesive polymer chains and entanglement of polymer and 
mucin chains. 
 Formation of weak chemical bonds 
 Sufficient polymer mobility to allow spreading 
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 Water transport followed by mucosal dehydration . 
As the mucus layer comes into contact with bioadhesive coated system, various non-
specific (Vander Waals, hydrogen bonding and/or hydrophobic interactions) or specific 
interactions occur between the complimentary structures. However, these interactions last 
only until the turnover process of mucin and, in order for a bioadhesive system to be 
successful; it should release its drug contents during this limited adhesion time. 32 
Raft-forming systems 
Here, a gel-forming solution (e.g. sodium alginate solution containing carbonates or 
bicarbonates) swells and forms a viscous cohesive gel containing entrapped CO2 bubbles on 
contact with gastric fluid. Formulations also typically contain antacids such as aluminium 
hydroxide or calcium carbonate to reduce gastric acidity. Because raft-forming systems 
produce a layer on the top of gastric fluids, they are often used for gastro esophageal reflux 
treatment as with liquid gaviscon.33 
                                        
Fig 11 Schematic illustration of the barrier formed by a raft-forming system 
Low density systems 
Gas-generating systems inevitably have a lag time before floating on the stomach 
contents, during which the dosage form may undergo premature evacuation through the 
pyloric sphincter. Low-density systems (<1 g/cm3) with immediate buoyancy have  
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therefore been developed. They are made of low-density materials, entrapping oil or air. Most 
are multiple unit systems, and are also called ‘‘microballoons’’ because of the low-density 
core .  Generally, techniques used to prepare hollow microspheres involve simple solvent 
evaporation or solvent diffusion methods. Polycarbonate, Eudragit S, cellulose acetate, 
calcium alginate, agar and low methoxylated pectin are commonly used as polymers. 
Buoyancy and drug release are dependent on quantity of polymer, the plasticizer–polymer 
ratio and the solvent used. 34 
 
Fig 12 (a) Microballoons (b) Foam-particles. 
Expandable systems 
A dosage form in the stomach will withstand gastric transit if it is bigger than the 
pyloric sphincter. However, the dosage form must be small enough to be swallowed, and 
must not cause gastric obstruction either singly or by accumulation. Thus, three 
configurations are required, a small configuration for oral intake, an expanded gastroretentive 
form and a final small form enabling evacuation following drug release. 
Unfoldable systems are made of biodegradable polymer; the concept is to make a 
carrier, such as a capsule, incorporating a compressed system, which extends in the stomach. 
Caldwell et al., 1988 proposed different geometric forms (tetrahedron, ring or planar 
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membrane (4-lobed, disc or 4-limbed cross form) of biodegradable polymer compressed 
within a capsule. 35 
 
Fig 13  Different geometric forms of unfoldable systems 
Swellable System 
Swellable systems are also retained because of their mechanical properties. The 
swelling usually results from osmotic absorption of water. The dosage form is small enough 
to be swallowed, and swells in gastric liquids, the bulk enable gastric retention and maintains 
the stomach in a ‘fed’ state, suppressing housekeeper waves.36 
Mamajek and Moyer patented drug reservoirs, surrounded by a swellable expanding 
agent. Urquhart and Theeqwes (1984) developed a system containing tiny pills, with a very 
high swelling ratio enabling up to 50 fold volume increase. They were coated by wax to 
control drug release and dispersed in a matrix of polymeric hydrogel. 37 
                         
Fig 14Swellable systems developed by Mamajek and Moyer (a) Urquhart and Theeuwes (b). 
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Superporous hydrogels 
Although these are swellable systems, they differ sufficiently from the conventional 
types to warrant separate classification (Chen and park, 2000) with pore size ranging between 
10 nm and 10 μm. Absorption of water by conventional hydrogel is very slow process and 
several hours may be needed to reach an equilibrium state during which premature 
evacuation of the dosage form may occur. Superporous hydrogel, average pore size > 100 
μm, swell to equilibrium size within a minute, due to rapid water uptake by capillary wetting 
through numerous interconnected open pores. Moreover they swell to a large size (swelling 
ratio 100 or more) (Figure 17) and are intended to have sufficient mechanical strength to 
withstand pressure by gastric contractions. This is achieved by a co- formulation of a 
hydrophilic particulate material, Ac-Di-Sol (crosscarmellose sodium).38 
In vivo studies with dogs showed that under fasting conditions, the superporous 
hydrogel composite (i.e. containing Ac-Di-Sol) remained in the stomach for 2-3 hours. This 
time increased to >24 hours after feeding, even though the fed condition was maintained only 
for a few hours. After several hours (30 hours), fragmentation occurred and the composite 
was rapidly cleared. 
 
Fig 15  superporous hydrogel in its dry (a) and water-swollen (b) state.  
schematic illustration of the transit of superporous hydrogel. 
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Magnetic system 
These systems appear as small gastroretentive capsules containing a magnetic 
material, whose elimination from the stomach is prevented by the interaction with a 
sufficiently strong magnet applied to the body surface in the region of the stomach. Despite 
numerous reports about successful tests, the real applicability of such systems is doubtful 
because the desired results can be achieved only provided that the magnet position is selected 
with very high precision. Probably, the development of new conveniently applied magnetic 
field sources will improve this concept. 39 
Self-unfolding systems 
The self-unfolding systems are capable of mechanically increasing in size relative to 
the initial dimensions. This increase prevents the system from passing via the pylorus and 
provides for its prolonged stay in the stomach. A drug can be either contained in a polymeric 
composition of the gastroretentive system or included as a separate component. Several 
methods were suggested to provide for the self-unfolding effect. 
 The use of hydrogels swelling in contact with the gastric juice. 
 Osmotic systems, comprising an osmotic medium in a semipermeable membrane. 
 Systems based on low-boiling liquids converting into a gas at the body 
temperature. 
This imparts to the system a desired volume and provides for the drug release. 
There are several problems for these systems, the main of which is the short swelling 
time (within several hours) insufficient for keeping the system in the stomach. 
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High density systems 
Gastric contents have a density close to water (1.004 g /cm3). When the patient is 
upright small high-density pellets sink to the bottom of the stomach where they become 
entrapped in the folds of the antrum and withstand the peristaltic waves of the stomach wall. 
A density close to 2.5 g/cm3 seems necessary for significant prolongation of gastric residence 
time and barium sulphate, zinc oxide, iron powder, titanium dioxide are used as excipients.40 
Development and evaluation of GFDDS: 
Formulation Development: 
For the optimum design of a GFDDS, the key step is to understand the principles of 
G.I.dynamics such as gastric emptying. Small intestinal transit, colonic transit etc. Acquiring 
knowledge about the rate and extent of drug absorption from different sites of G.I sites, and 
factors that can alter or limit the absorption further aid I the designing the type of dosage 
form that is needed for a particular drug. For instance with drugs such as sulpiride, 
furosemide, theophylline and albuterol, which are predominantly absorbed from the upper 
part of the G.I tract, designing a gastric retention dosage form is a logical strategy for 
improving and extending their limited oral bioavailabilities41-44. For the formulation of a 
Hydrodynamically balances dosage forms, three major conditions must be met: 
 It must have sufficient structure to form a cohesive gel barrier: 
 It must maintain an overall density lower than that of gastric contents (reported as 
1.004- 1.01g/cc) and 
 It should dissolve slowly, enough to serve as a .reservoir. for the delivery system. 
The task of designing a dosage forms to achieve a consistent and controlled residence 
in the stomach begins with selection of potential excepients that allow the formulation of the 
matrices having sustained delivery characteristics and a bulk density of less than unity. As far 
as the ideal floating dosage forms is concerned, it should have high buoyancy, adequate 
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mechanical strength, excellent acid resistance and a high drug releasing capacity in the 
stomach. Ideally water-soluble cellulose derivatives are best suited for such purposes. 
 In vitro and In vivo evaluation: 
The various parameters that need to be evaluated for their effects on gastric retention time of 
buoyant formulations can mainly be categorized into following different classes. 45 
 Galenic parameters: dimeteral size (. cut-off size.), flexibility and density of matrices. 
 Control parameters: floating time, dissolution, content uniformity, hardness and 
friability. 
 Geometric parameters: shape. 
 Physiological parameters: age, sex posture, food and bioadhesion. The test for 
buoyancy and in vitro drug release studies are usually carried out in simulated gastric 
fluid maintained at 37oC. The in vivo gastric retentivity of a floating dosage forms is 
usually determined by gamma scintillography or roetgenography.46 Studies are done, 
both under fasted and fed conditions using floating and non floating (control) dosage 
forms. It is also important that both dosage forms are non-disintegrating units, and 
human subjects are young and healthy. 
 
 
 INFLAMMATION 
A morbid condition of any part of the body, consisting in congestion of the blood vessels, 
with obstruction of the blood current, and growth of morbid tissue. It is manifested outwardly 
by redness and swelling, attended with heat and pain. The classical signs of acute 
inflammation are pain (dolor), heat (calor), redness (rubor), swelling (tumor), and loss of 
function. 
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Inflammation (Latin, inflammare, to set on fire) is part of the complex biological response of 
vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. 
Inflammation is a protective attempt by the organism to remove the injurious stimuli and to 
initiate the healing process.47 Inflammation is not a synonym for infection, even in cases 
where inflammation is caused by infection. Although infection is caused by a microorganism, 
inflammation is one of the responses of the organism to the pathogen. 
Without inflammation, wounds and infections would never heal. Similarly, progressive 
destruction of the tissue would compromise the survival of the organism. However, chronic 
inflammation can also lead to a host of diseases, such as hay fever, atherosclerosis, 
rheumatoid arthritis, and even cancer (e.g., gallbladder carcinoma). It is for that reason that 
inflammation is normally closely regulated by the body. 
Inflammation can be classified as either acute or chronic. Acute inflammation is the initial 
response of the body to harmful stimuli and is achieved by the increased movement of plasma 
and leukocytes (especially granulocytes ) from the blood into the injured tissues. A cascade 
of biochemical events propagates and matures the inflammatory response, involving the local 
vascular system, the immune system, and various cells within the injured tissue. Prolonged 
inflammation, known as chronic inflammation, leads to a progressive shift in the type of cells 
present at the site of inflammation and is characterized by simultaneous destruction and 
healing of the tissue from the inflammatory process.48 
 
Mechanism of action: 
Most of the non-selective NSAIDs as inhibitors against cyclooxygenase enzymes, 
cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isozymes. Cyclooxygenase 
catalyst to the formation of prostaglandins and thromboxane from arachidonic acid ( itself is 
obtained from the porous phospholipid bilayer by the phospholipase A2). prostaglandin as a 
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(particular) messenger molecule in the inflammation process. This mechanism of action has 
been clarified after John received a Nobel Prize for the flap of his work (see aspirin ling 
mechanism of action). Recently discovered COX-3 could also have a role. 49 
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2. AIM AND OBJECTIVES 
 
Floating tablets are useful for those drugs that act locally in the gastrointestinal tract 
(GIT), are unstable in lower parts of GIT, or are poorly absorbed in the intestine45,46 
Aceclofenac (2-[(2, 6-dichlorophenyl) amine] phenylacetoxyacetic acid) is a newer 
non-steroidal anti-inflammatory drug (NSAID). Aceclofenac is a phenyl acetic acid 
derivative showing effective anti-inflammatory and analgesic properties mainly used in 
osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Aceclofenac is rapidly and 
efficiently absorbed after oral administration but has a short half life of 3-4 h and requires 
multiple dosing for maintaining therapeutic effect throughout the day. Its biological half-life 
is very short, sustaining its anti-inflammatory activity only for a few hours and associated 
adverse effects; it is considered an ideal model drug for floating matrix drug delivery. 
In fact there is a need to develop a dosage form to deliver aceclofenac in the stomach 
and to increase the efficiency of the drug, providing targeted action. The objective of this 
study was to prepare floating matrix tablets of aceclofenac using HPMC, carbopol and guar 
gum. 
The purpose of this project was to prepare a floating drug delivery system of 
aceclofenac. Floating drug delivery system makes the dosage form to float on the gastric 
fluid. These can remain in the gastric part for several hours and hence significantly prolong 
the gastric residence time of the aceclofenac. 
 
The overall aim and object of the present work was 
 Formulation of floating tablets for Aceclofenac (AF1 – AF5) 
 Evaluation of formulated product (AF1 – AF5) 
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3. LITERATURE REVIEW 
 
 Akbari et al, (2010)50 prepared floating tablets using direct compression techniques 
using polymers like HPMC K4M and HPMCK100M. The HPMC polymer alone is 
unable to control release rate. It releases drug >90% in four to six hours. In 
combination with Xanthan gum it release >90% in eight hours. The results indicate 
that gas generated gastroretentive ﬂoating tablets of famotidine containing 
HPMCK100M and Xanthan gum provide better options for controlled release action 
and improved bioavailability. 
 Ravi Kumar et al, (2009) 51 developed floating matrix tablets of aceclofenac to 
prolong gastric residence time and to increase bioavailability. Rapid gastrointestinal 
transit could result in incomplete drug release from the drug delivery system above 
the absorption zone leading to diminished efficacy of the administered dose. Floating 
matrix tablets containing 100 mg aceclofenac were developed using different bees 
wax combinations. The tablets were prepared by melt granulation technique, using 
polymers such as hydroxypropylmethylcellulose (HPMC K15M), ethyl cellulose, bees 
wax, cetyl alcohol, glycerin monostearate alone or in combination and other standard 
excipients. Sodium bicarbonate was incorporated as a gas-generating agent. 
 Orazio SL et al, (2008)52 studied in vivo by resultant-weight measurement and in 
vivo by -scintigraphy experiment in humans, the floating behavior of system 
obtained by modules assembled in void configuration. the floating of the system 
immediately and lasted for more than 5 h. 
 Quan Liu and Reza Fassihi (2008)53 prepared a zero order delivery of a highly 
soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system which 
were prepared as two multilayer delivery systems. First formulation compressed a 
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triple layer based on PEO while the second formulation was a bilayer composite 
matrix system composed of HPC and HPMC. The observation showed that the 
systems demonstrated controlled release kinetics independent of pH changes with 
about 99% of dose being released around 18h. The maintenance of constant surface 
area during dissolution is critical for zero-order drug delivery. The burst release 
suppression effect brought about by raped initial swelling and controlled erosion of 
layers provided for programmed controlled delivery and enhanced floatation 
 Jaimini et al, (2007)54 investigated the effect of citric acid on drug release profile.  
The prepared tablets exhibited satisfactory physicochemical characteristics.  All the 
prepared batches showed good in vitro buoyancy. The tablet swelled radially and 
axially during in vitro buoyancy studies. It was observed that the tablet remained 
buoyant for 6-10 hours. Decrease in the citric acid level increased the floating lag 
time but tablets floated for longer duration. A combination of sodium bicarbonate 
(130mg) and citric acid (10mg) was found to achieve optimum in vitro buoyancy.     
 Manoj et al, (2007)55 prepared floating drug delivery system of diltiazem 
hydrochloride using polymers such as HPMC K100M CR and compritol 888 ATO, 
alone and in combination. The effect of sodium bicarbonate and succinic acid on drug 
release was investigated. The high level of both methocel K100M CR and compritol 
888 ATO favoured the preparation of floating controlled release of diltiazem tablets. 
It was observed that incorporation of succinic acid in the formulation nullified the 
effect of the acidic dissolution media on the drug release in this formulation, methocel 
K100M CR retards the release by diffusion mechanism and compritol 888 ATO 
decreases the hydration of matrix and retards the release by erosion mechanism owing 
to its hydrophobic property. Together, these polymers retard the release of drug using 
different mechanisms 
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 Talukder et al, (2006)56 developed a floating multi particular system with potential 
for intra-gastric sustained drug delivery .Cross-linked beads were made by using low 
methoxylated pectin and sodium alginate .Riboflavin, tetracycline and methotrexate 
were used as model drugs for encapsulation. It appeared that the nature of cross-
linking, drug solubility and production approach were important and provide the 
opportunity and potential for development of a gastro retentive drug delivery system. 
 Narendra et al, (2006)57 developed an optimized gastric floating dosage form 
containing metoprolol tartrate as model drug. The results showed that total polymer 
content to drug ratio and polymer to polymer ratio significantly affect the floating 
time and drug release property of formulated bilayer tablets. 
 Patel et al, (2006)58 investigated an intragastric drug delivery system for cefuroxime 
axetil to evaluate the contribution of HPMC K4M/HPMC K100 LV ratio and the SLS 
on drug release. Formulations were evaluated  for in vitro buoyancy and drug release 
study using  USP 24 paddle type dissolution apparatus using 0.1 N HCl as a 
dissolution medium. It was found that the polymer blend and SLS greatly affect the 
dissolution parameters. 
 Bardonn et al, (2006)59 reviewed and summarized the important physiologic 
parameters, which act upon the gastric residence time and different drug delivery 
systems i.e. high-density, intragastric floating, expandable, superporous hydrogel, 
mucoadhesive and magnetic systems 
 Shweta et al, (2005)60 reviewed on floating drug delivery systems with special focus 
on the principal mechanism of floatation to achieve gastric retention. The recent 
developments of FDDS including the physiological and formulation variables 
affecting gastric retention, approaches to design single-unit and multiple-unit floating 
systems, and their classification and formulation aspects are covered in detail. This 
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review also summarizes the in vitro techniques, in vivo studies to evaluate the 
performance and application of floating systems, and applications of these systems. 
 Basak SC et al, (2004)61 formulated a floating matrix using ciprofloxacin as model 
drug.the formulation consist of sodium bicarbonate (gas generating agent), HPMC , 
lactose and PVP .the in vivo drug release studies showed sustained release of 
ciprofloxacin up to 80-89% for 8h. 
 Ozdermis et al, (2004)62 prepared floating dosage to enhance the bioavailability of 
furosemide. The solubility was increased by forming inclusion complex with betadex 
(beta cyclodexterin). Dissolution studies and floating time was studied. The plasma 
AUC values of floating dosage forms were about 1.8 times greater than those of the 
conventional tablet. 
 Eikheshen et al, (2004)63 prepared a sustained release floating system for verapamil 
HCl using different polymers, which are HPMC, HPC and ethyl cellulose.Floating 
was maintained gy adding effervescent mixture of sodium bicorbonates and citric 
acid.Results showed that HPMc has floating property. 
 Wei et al, (2004)64 developed a pH dependent floating sustained release tablet for 
gastric retention of 5-FU and prepared two layer floating tablet wherein floating 
ability is independent of the gastric acidity variation. 
 Li et al, (2003)65 investigated the effect of formulation variables on the calcium 
release and floating properties of the delivery system by using 2x3 factorial designs 
by using different grades of Hydroxypropylmethylcellulose (K100LV and K4M) and 
carbopol. They reported that by increasing the HPMC viscosity the release rate 
decreases and floating properties improved as the viscosity of the polymer is 
increased. Carbopol (CP934) incorporation was found to compromise the floating 
capacity of floating and release of calcium 
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 Shoufeng Li et al, (2002)66 found that both HPMC viscosity, the presence of  
carbopol and their interaction had signiﬁcant impact on the release and ﬂoating 
properties of the delivery system. The decrease in the release rate was observed with 
an increase in the viscosity of the polymeric system. Polymer with lower viscosity 
(HPMC K100LV) was shown to be beneﬁcial than higher viscosity polymer (K4M) in 
improving the ﬂoating properties of GFDDS. Incorporation of Carbopol, however, 
was found to compromise the ﬂoating capacity of GFDDS and release rate of calcium. 
 Nur and Zhanj (2000)67 prepared captopril floating and bioadhesive tablets using 
two grade of HPMC (400 and 15000cps) and carbopol 934P. In vivo dissolution was 
carried out in simulated gastric fluid (enzyme free) at 37 ± 0.1°C using the USP type 
II method. Compared to conventional tablets, release of captopril from these floating 
tablets was apparently prolonged (24hrs). Tablet hardness was found to be a 
determining factor with regard to the buoyancy of the tablets. 
 Iannuccelli et al, (2000)68 used PVP solid dispersions for the controlled release of 
furosemide from a floating multiple-unit system. The complete dose release over the 
actual intra-gastric residence time of the system (about 8 hr) was achieved by loading 
both the core and the membrane forming the units with 1:5 furosemide: PVP solid 
dispersion. Physicochemical analysis suggested that amorphous state of furosemide 
enhanced drug solubility and dissolution rate, which led to the desired release profile 
from the floating units. 
 Ozdemir et al, (2000)69 developed floating bilayer tablet of furosemide- cyclodextrin 
inclusion complex. They determined the gastric residence time using radiographs by 
adding BaSO4 and reported that the tablet stayed in stomach for 6 hours. Also the 
bioavailability of furosemide from floating tablet was about 1.8 times that of the 
conventional tablet and also significant in vitro – in vivo correlation was detected. 
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 Krogel and Bodmeier (1999)70 developed and evaluated floating drug delivery 
system based on effervescent core and a polymeric coating. The mechanical 
properties (puncture strength and elongation) of acrylic (Eudragit RS, RL and NE) 
and cellulose (cellulose acetate, ethyl cellulose) polymer, which primarily determined 
the type of delivery system, a polymer coating with a high elongation value and high 
water low carbon dioxide permeability was selected (Eudragit RL/ acetyl tributyl 
citrate 20%w/w) in order to initiate the effervescent reaction and the floating process 
rapidly. HPMC was also added in the core to retard drug release. The composition and 
hardness of the tablet core and the composition and hardness of the coating could 
control the time of flotation. 
 Lee et al, (1999)71 prepared floating acrylic resin microspheres with an internal 
hollow structure by a solvent diffusion and evaporation method. The yield of 
microspheres depended on the diffusion rate of ethanol and/or isopropanol in the 
gastric phase. Best results were obtained at the volume ratio of Ethanol: Isopropanol: 
dichloromethane (8:2:5). When a drug had low solubility in dichloromethane, the 
loading efficiency was the lowest. 
 Chen and Hao (1998)72 studied the in vitro performance of floating sustained release 
capsule of verapamil. Capsules filled with mixture of verapamil, HPC and 
effervescent materials are proposed to provide floating and sustained release for over 
10 hrs. The effects of weight filled in the capsule, amount of HPC and the addition of 
effervescent material on the dissolution kinetics were studied. They concluded that the 
release of Verapamil from the capsule followed Higuchi release model. However, 
when effervescent material was added, the system showed a zero-order release. 
 Atyabi F et al, (1996)73 prepared floating ion exchange resin beads. Beads were 
loaded with bicarbonate and coated with a semi permeable membrane .These beads 
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exhibited  a prolonged gastric residence due to release of carbon dioxide that was 
trapped inside the coating of the beads .A model drug theophylline has been loaded on 
to the resin .The beads produced a controlled release pattern of drug. 
 Menon et al, (1994)74 reported the formulation of a monolithic floating dosage form 
for Furosemide using factorial design keeping the drug to polymer ratio, polymer to 
polymer ratio and polymer grade as the three factors. The optimized formulation thus 
obtained was found to have a good in vitro - in vivo correlation. 
 Desai and Bolton (1993)75 developed controlled release floating tablets of the 
theophylline using agar and light mineral oil. Tablets were made by dispersing drug 
and mineral oil mixture in a warm agar solution. The resultant mixture was poured 
into tablets moulds, which on cooling and air-drying formed floatable CR tablets. The 
light mineral oil was essential for the floating property of the tablets since relatively 
high amount of the drug (75%) was used. 
 Gerogiannis et al, (1993)76 examined the floating and swelling characteristics of 
several excipients used in controlled release technology. The floating behavior was 
evaluated with resultant weight measurements, while a gravimetric method was 
employed for studying their swelling. The results indicated that higher molecular 
weight polymers had slower rates of polymer hydration and usually followed by 
enhanced floating behavior. 
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DRUG PROFILE- ACECLOFENAC 77,78 
Generic Name 
Aceclofenac 
Trade Name 
Acefen, Acefen p, Acenac, Dolokind 
Molecular mass 
354.18472g/mol 
Molecular formula 
C16H13CL2NO4 
Melting point 
149-153OC 
IUPAC name 
2-[2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl] ox acetic acid                                                  
 
Aceclofenac is an orally administered phenyl acetic acid derivatives with effects on a  
variety of inflammatory mediators. 
                                            
Fig 16 Aceclofenac 
Aceclofenac contains not less than 99.0% and not more than the equivalent of 101.0 
percent of 2-[[2-[2-[(2, 6-dichlorophenyl) amino] phenyl] acetyl] oxy] acetic acid. 
It is a white or almost white crystalline powder. It is an effective analgesic and anti-
inflammatory agent with a good tolerability profile. Through its analgesic and anti-
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inflammatory properties, aceclofenac provides symptomatic relief in a variety of painful 
conditions. 
Solubility 
Practically insoluble in water, freely soluble in acetone, soluble in alcohol. 
Storage 
In an air tight container, protected from light. 
Pharmacology 
The mode of action of aceclofenac is largely based on the inhibition of prostaglandin 
synthesis. Aceclofenac is a potent inhibitor of the enzyme cyclooxygenase, which is involved 
in the production of prostaglandins. 
The drug inhibits synthesis of the inflammatory cytokines interleukin (IL)-1 and 
tumor necrosis factor and prostaglandin E2 (PGE2) production. Effects on cell adhesion 
molecular from neurophils have also been noted. In vitro data indicate inhibition of 
cyclooxygenase (Cox)-1 and 2 by aceclofenac in whole blood assays, with selectivity for 
Cox-2 being evident. 
Aceclofenac has shown stimulatory effects on cartilage matrix synthesis that may be 
linked to the ability of the drug to inhibit IL-1 activity. In vitro data indicate stimulation by 
the drug of synthesis of glycosaminoglycan in osteoarthritis cartilage. There is also evidence 
that aceclofenac stimulates the synthesis of IL-1 receptor antagonist in human articular 
chondrocytes subjected to inflammatory stimuli and that 4'-hydroxyacelofenac has 
chondroprotective properties attributable to suppression of IL-1 mediated promatrix 
metalloproteinase production and proteoglycan release. 
In patients with osteoarthritis of the knee, aceclofenac decrease pain reduces disease 
severity and improves the functional capacity of the knee. It reduces joint inflammation, pain 
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intensity and the duration of morning stiffness in patients with rheumatoid arthritis. The 
duration of morning stiffness and pain intensity are reduced and spinal mobility improved, by 
aceclofenac in patients with ankylosing spondylitis. 
PHARMACOKINETICS 
Aceclofenac is rapidly and completely absorbed after oral administration, peak 
plasma concentrations are reached 1 to 3 hours after an oral dose. The drug is highly protein 
bound (7.99%). The presence of food does alter the extent of absorption of aceclofenac but 
the absorption rate is reduced. The plasma concentration of aceclofenac was approximately 
twice that in synovial fluid after multiple doses of the drug in-patient with knee pain and 
synovial fluid effusion.  
Aceclofenac is metabolized to a major metabolite, 4'-hydroxyaceclofenac and to a 
number of other metabolites including 5-hydroxyaceclofenac, 4'-hydroxydiclofenac, 
diclofenac and 5-hydroxydiclofenac. Renal excretion is the main route of elimination of 
aceclofenac with 70 to 80% of an administered dose found in the urine, mainly as the 
glucuronides of aceclofenac and its metabolites of each dose of aceclofenac, 20% is excreted 
in the faeces. The plasma elimination half-life of the drug is approximately 4 hours. 
Adverse Drug Reaction 
Aceclofenac is well tolerated, with most adverse events being minor and reversible 
and affecting mainly the GI system. Most common events include dyspepsia (7.5%), 
abdominal pain (6.2%), nausea (1.5%), diarrhea (1.5%), flatulence (0.8%), gastritis (0.6%), 
constipation (0.5%), vomiting (0.5%), ulcerative stomatitis (0.1%), pancreatitis (0.1%). 
Although the incidence of gastro intestinal adverse events with aceclofenac was similar to 
those of comparator NSAIDS in individual clinical trials, withdrawal rates due to these events 
were significantly lower aceclofenac than with ketoprofen and tenoxicam. 
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Other adverse effect, which is not common such as dizziness (1%), vertigo (0.3%), and rare 
cases: par aesthesia and tremor. 
Dosage and Administration 
The usual dose of aceclofenac is 100 mg given twice daily by mouth, one tablet in the 
morning and one in the evening. There is no evidence that the dosage of aceclofenac needs to 
be modified in patients with mild renal impairment, but as with other NSAIDS caution should 
be exercised. 
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POLYMER PROFILE 
HPMC79,80,81 
Structural unit 
 
Fig 17 Structure of  HPMC 
Non-proprietary Name 
Hydroxymethylcellulose.  
Synonyms 
Hydroxypropylmethyl ether, methylhydroxypropylcellulose methylcellulose, 
methocel.  
Chemical name 
Cellulose,  2-hydroxypropyl methylcellulose.  
Application 
Hypromellose is widely used in oral and topical pharmaceutical formulations. 
Hypromellose is used as tablet binder, in film coating and as an extended release tablet 
matrix. Concentrations between 2% and 5% w/w may be used as a binder in either wet or dry 
granulation processes.  
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Hypromellose is also used as a suspending agent and thickening agent in topical 
formulations particularly in ophthalmic preparations. Hypromellose is also used as an 
adhesive in plastic bandages and as a wetting agent for hard contact lenses.  
Solubility 
Soluble in cold water, forming a viscous colloidal solution, practically insoluble in 
chloroform, ethanol and ether. But it is soluble in mixtures of methanol and dichloromethane 
and mixtures of water and alcohol.  
Description 
Hypromellose is an odorless and tasteless, white or creamy or granular, powder.  
pH 
1% w/w solution 5-8 
Viscosity 
A wide range of viscosity HPMC is available. HPMC E50 Viscosity 50 mPas.  
Stability storage 
Hypromellose is stable powder, but after drying it is hygroscopic. Solutions are stable 
at ph 3-11 increasing temperature reduced the viscosity of solutions. Hypromellose is 
aqueous solutions are comparatively enzyme-résistance, providing good viscosity stability 
during long-term storage. It is liable to microbial spoilage; benzalkonium chloride is 
commonly used preservative.  
Incompatibilities 
Hypromellose is incompatible with some oxidizing agents.  
CARBOPOL 94079,80,81 
Nonproprietary Names :        
BP: Carbomers,  
PhEur: Carbomera  
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USPNF: Carbomer  
Synonyms 
Acritamer; acrylic acid polymer; Carbopol; carboxy polymethylene, polyacrylic acid; 
carboxyvinyl polymer; Pemulen; Ultrez.  
Chemical Name 
Carbomer  
Molecular Weight  : 
3x10
6
D 
Functional Category  
Bio adhesive, Emulsifying  agent, suspending  agent, tablet       binder, viscosity 
increasing agent, Release modifying agent.  
Application in Pharmaceutical Formulation or Technology 
Carbopol 940 is used mainly in liquid or semisolid pharmaceutical formulations as 
suspending or viscosity increasing agent. Formulation including Creams, gels and ointments 
for in ophthalmic rectal and topical preparations. In the tablet formulations carbomers are 
used as dry or wet binder and as a rate controlling excipients.  
Carbomer resins have also been investigated in the preparation of sustained release 
matrix beads, as enzyme inhibitors of intestinal proteases in peptide containing dosage forms, 
as a bioadhesive patch for cervical patch and for intranasally administered microspears, in 
magnetic granules for site specific drug delivery to the esophagus and in oral mucoadhesive 
controlled drug delivery system 
Stability and Storage Conditions 
Carbopol is stable and should be stored in tight containers.  
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Incompatibilities 
Carbomer are discolored by resorcinol and are incompatible with phenol, cationic 
polymers strong acids and high level of electrolyte  
Safety 
It is regarded as essentially nontoxic and nonirritant materials. 
GUAR GUM79,80,81 
Synonyms   
Galactosol; Gaurflour; jaguar gum; Meprogat.                
Chemical name  
Galactomannan polysaccharide 
Empirical formula  
 (C6H12O6) n 
Molecular weight  
  ≈ 220 000 
Structural formula  
Gaur gum consists of linear chains of (1→4)-β-D-manno-pyranosyl units with  
α-D-galactopyranosyl units attached by (1→6) linkages. The ratio of D-galactose to D- 
mannose is 1: 1.4 to 1:2.  
 
 
 
 
Fig 18 Structure of guar gum 
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Description 
The USPNF 20 describes guar gum as a gum obtained from the ground endosperms of 
cyamopsis tetragonolobus (Fam: Leguminosae). 
Colour      
 White to yellowish white 
Odour        
Odorless or nearly odorless 
Taste         
Bland taste 
Texture         
Powder 
Acidity / Alkalinity        
pH 5.0 to 7.0 (1% w/v aqueous     dispersion) 
Viscosity        
 4.86 Pas for 1% w/v dispersion  
Solubility 
In organic solvents disperses and swells immediately in cold or hot water to form a 
highly viscous and thixotropic solution. 
Functional category 
Suspending agent, Tablet binder, Tablet disintegrate, Viscosity increasing agent        
Applications in pharmaceutical technology 
 Used in solid dosage forms as a binder (up to 10%) and disintegrant 
 Used in oral and topical products as a suspending, thickening (up to 2.5%) and 
stabilizing agent (1%) 
 Used in colon targeted drug delivery systems 
 Used as an appetite suppressant 
 Also, used in cosmetic and food products  
Storage 
It should be stored in a well closed container and kept in cool and dry place. 
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Incompatibilities 
It is incompatible with acetone, alcohol, tannins, strong acids and alkalis. 
Presence of borate ions in distilled water, will prevent 
SODIUM CARBOXYMETHYLCELLULOSE 79,80,81 
Brand name 
Akucell; Aquasorb; Blanose; Cellulose gum; Cmc Sodium; E466; Finnfix; Nymcel; SCMC; 
Sodium Carboxymethylcellulose; Sodium Cellulose Glycolate; Sodium Cmc; Tylose Cb. 
Description 
Color 
white to almost white, 
 Odor   
Odorless 
Solubility  
Practically insoluble in acetone, ethanol, ether, and toluene.  
Functional category 
Coating agent; tablet and capsule disintegrant; tablet binder; stabilizing agent; 
suspending agent; viscosity-increasing agent; water-absorbing agent. 
Applications in pharmaceutical formulation 
 Carboxymethylcellulose sodium is widely used in oral and topical pharmaceutical 
formulations, primarily for its viscosity-increasing properties. Viscous aqueous 
solutions are used to suspend powders intended for either topical application or oral 
and parenteral administration. 
 Carboxymethylcellulose sodium may also be used as a tablet binder and disintegrant, 
and to stabilize emulsions. 
 Carboxymethylcellulose sodium is also used in cosmetics, toiletries and incontinence, 
personal hygiene, and food products. 
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Stability  
Carboxymethylcellulose sodium is a stable, though hygroscopic material. Under high-
humidity conditions, carboxymethylcellulose sodium can absorb a large quantity (>50%) of 
water.  
Aqueous solutions are stable at pH 2–10; precipitation can occur below pH 2, and 
solution viscosity decreases rapidly above pH 10. Generally, solutions exhibit maximum 
viscosity and stability at pH 7–9. 
Storage 
Aqueous solutions stored for prolonged periods should contain an antimicrobial 
preservative. 
The bulk material should be stored in a well-closed container in a cool, dry place. 
 Incompatibilities 
Carboxymethylcellulose sodium is incompatible with strongly acidic solutions and 
with the soluble salts of iron and some other metals, such as aluminum, mercury, and zinc. 
Precipitation may occur at pH <2, and also when it is mixed with ethanol (95%). 
Carboxymethylcellulose sodium forms complex coacervates with gelatin and pectin. 
It also forms a complex with collagen and is capable of precipitating certain positively 
charged proteins. 
 SafetyCarboxymethylcellulose sodium is used in oral, topical, and some parenteral 
formulations. The WHO has not specified an acceptable daily intake for 
carboxymethylcellulose sodium as a food additive since the levels necessary to achieve a 
desired effect were not considered to be a hazard to health.  
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4. PLAN OF WORK 
1. PREFORMULATION STUDIES 
i. Compatibility studies 
ii. Flow property 
 Bulk density 
 Tapped density 
 Hausner’s ratio 
 Carr’s index 
 Compressibility index 
 Angle of repose 
 
2. FORMULATION STUDIES 
          Formulation of floating tablets of aceclofenac using different polymers (AF1-AF5) 
 
3. EVALUATION STUDIES 
a. Hardness, Friability, LOD, average weight 
b. Buoyancy lag time. 
c. Duration of floating 
d. Drug content 
e. Swelling study  
f. Dissolution  
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5. MATERIALS AND METHODS 
 
Table 3 Materials Required 
 
S.NO 
 
MATERIALS 
 
SOURCE 
 
1 
 
Aceclofenac 
 
Medopharm, Chennai 
 
2 
 
HPMC 
 
Otto Chemika-Biochemika reagents, Mumbai 
 
3 
 
Carbopol 940 
 
Otto Chemika-Biochemika reagents, Mumbai 
 
4 
 
Guar gum 
 
Loba Chemie Pvt, Ltd,Mumbai 
 
5 
 
Acacia gum 
 
Loba Chemie Pvt, Ltd,Mumbai 
 
6 
 
Citric acid 
 
Sisco Research Laboratories Pvt Ltd, Mumbai 
 
7 
 
Sodium bicarbonate 
 
Sisco Research Laboratories Pvt Ltd, Mumbai 
 
8 
 
SCMC 
 
Indian Research Products, Chennai 
 
9. 
 
Magnesium stearate 
 
Loba Chemie Pvt, Ltd, Mumbai 
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Table 4 Equipments required 
 
S.NO. 
 
EQUIPMENT 
 
SOURCE 
 
1 
 
Tablet compression machine 
 
Rimek, minipress, UK 
 
2 
 
Hot air oven for drying  
 
Hicon, New Delhi. 
 
3 
 
Electronic balance 
 
Sartorious, Germany 
 
4 
 
Bulk density apparatus 
 
Veego, Mumbai 
 
5 
 
Dissolution apparatus 
 
Electrolab Mumbai 
 
6 
 
Friabilator 
 
EF - 2 Electrolab, Mumbai 
 
7 
 
Hardness testing apparatus 
 
Tablet hardness tester, Monsanto 
 
8 
 
Melting point apparatus 
 
Campbell Electronics, Mumbai 
 
9 
 
pH meter 
 
Digisun Electronics. Hyderabad 
 
10 
 
FTIR 
 
Alphar T0, Bruker, New Delhi 
 
11 
 
UV-Spectrophotometer 
 
UV-1700, Shimadzu, Mumbai 
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METHODS 
PREFORMULATION STUDIES 80,81 
Preformulation is defined as application of biopharmaceutical principles to the 
physicochemical properties of the drug. It is a phase of R & D process. 
FTIR Spectroscopy 
IR spectra of aceclofenac, was obtained by a Perkin-Elmer Fourier transform infrared 
spectrophotometer using KBr pellets.  
Melting point 
Aceclofenac MP was measured by capillary tube method.  
Loss on drying 
10gms Aceclofenac was heated to a temperature of 105ºC in hot air oven until it 
remains constant weight. The formula was 
 
 
       The results were recorded and given in the results and discussion. 
Angle of repose 
It was measured by fixed funnel technique. In this technique a funnel containing 
aceclofenac was kept at a fixed height, and it was allowed to flow to the surface which 
contains graph paper. This is due to gravitational force. The height and radius of the heap 
formed was measured. The formula for angle of repose (θ) was  
θ = tan-1(h/r) 
The results were recorded and given in results and discussion. 
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Bulk density & Tapped density: 
Bulk densities of granules were determined by pouring gently 20 gm of sample 
through a glass funnel into a 100 ml graduated cylinder. The volume occupied by the sample 
was recorded. Bulk density and tapped density were calculated by the formula 
 
 
 
The results were recorded and given in the results and discussion. 
 
Compressibility Index 
CI of the powder was determined from the bulk and tap density as follows4 
 
The results were recorded and given in the results and discussion. 
Hausner’s ratio 
It was calculated as 
 
 
 The results were recorded and given in the results and discussion. 
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COMPATIBILITY STUDIES  
IR Spectroscopy 
IR spectra of pure aceclofenac, polymer and combination of aceclofenac with polymers were 
obtained by using Perkin-Elmer Fourier transform infrared spectrophotometer. The scanning 
range used was 4000 to 400cm-1. 82 
The results were recorded and given in the results and discussion. 
 
STANDARD GRAPH OF ACECLOFENAC:  
Standard graphs of the drug were prepared using standard aceclofenac solution in acid 
buffer pH 1.2, phosphate buffer pH 6.8 & pH 7.4 containing 5 to 50μg. The absorbance was 
measured at 275nm. Linear relationship was observed with absorption to concentration of 
drug.  The values of absorbance related to concentration were given in table 6 and graphs 
were given in fig 19. 
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FORMULATION 
Table 5 Formulation trails of Aceclofenac floating tablets (AF1 – AF5) 
 
S.NO 
 
INGREDIENTS 
AF1 
(mg) 
AF2 
(mg) 
AF3 
(mg) 
AF4 
(mg) 
AF5 
(mg) 
1 Aceclofenac 200 200 200 200 200 
2 HPMC 200 _ _ 100 100 
3 Carbopol 940 _ 200 _ 100 _ 
4 Guar gum _ _ 200 _ 100 
5 Citric acid 20 20 20 20 20 
6 Sodium CMC 20 20 20 20 20 
7 Sodium bicarbonate 20 20 20 20 20 
8 Magnesium stearate 5 5 5 5 5 
9 Talc 5 5 5 5 5 
Total Weight 470 470 470 470 470 
 
 
Aceclofenac floating tablets were prepared by direct compression method using 
excipients and polymers to release the drug sustainably after administration 
 Accurately weighed quantities of excipients were placed in a mortar and gradually 
mixed with constant kneading to ensure homogenous mass. Then the homogenous powder 
was passed through sieve number 40 and the powder was retained on sieve number 100. Then 
the powder was lubricated with magnesium stearate and talc. Then the powder was directly 
compressed into tablets on a tablet punching machine. 
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EVALUATION OF FLOATING TABLETS 
Standard graph of Aceclofenac  
The λ max of aceclofenac in 0.1 N HCl was scanned to be 275 nm using UV spectrometer. 
The standard graph of aceclofenac was dissolved in required quantity of 0.1N HCl and made 
up the volume 100 ml using 0.1N HCl. To obtain the stock solution of concentration 1mg/ml, 
from this 1 ml was taken and diluted to 100ml using 0.1N HCl to obtain working stock 
solution of concentration. From the above solutions 5, 10, 15, 20,2 5ml was taken to dilute to 
10ml using 0.1N HCl to obtain the concentration of 5,10,15,20,25µg/ml. 
 
EVALUATION OF PHYSICAL PROPERTIES 
i.  Weight variation 
Weigh 20 tablets selected at random and calculate the average weight. Not more than 
two of the individual weights deviate from the average by more than the percentage 
shown in table below and none deviates by more than twice that percentage. 
ii.  Friability  
20 tablets were weighed and placed in the Roche friabilator where the tablets were 
exposed to rolling and repeated shocks resulting from free falls within the apparatus, 
after 100 revolutions, the weighed again. The friability was determined as the 
percentage loss in the weight of the tablets. A loss of less than 0.5 to 1% in weight is 
generally considered acceptable. 
iii.  Hardness  
                Hardness was measured using Pfizer hardness tester which measure the pressure 
required to break the diametrical placed tablets by the pressure with coiled spring. 
iv.  Content uniformity :  
It is the amount present in each formulation for formulation (or tablets) 
57 
 
Tablets from formulation was taken and dropped in 100ml 0.1N HCl in a beaker. 
After 24 hrs or when the drug is released completely the same sample was withdrawn 
(about 1ml) and diluted to 10ml with 0.1N HCL and absorbance was taken at 275nm 
using UV spectrometer. From the standard graph % drug release was calculated. 
v.  Thickness:  
The thickness of the tablet is measured by using screw gauge. It gives the changes in 
weight variation of the tablet 
vi.  Floating lag time:  
The floating lag time is determined in order to assess the time taken by the dosage to 
float on the top of the dissolution medium, after placing the dosage form in the 
medium. 
vii.  Floating time:  
It is the time the tablet constantly floats on the dissolution medium (i.e duration of 
floating) in the dissolution medium. 
 
viii. Dissolution studies:  
Aceclofenac floating tablets were kept in dissolution medium 0.1N HCl (900ml) for 
initial 2 hours and operated at temperature 37±0.50C and rotated at 75 rpm. Then pH 
6.8 phosphate buffer (900ml) was used as dissolution medium. Freshly prepared 
dissolution medium is used always.  Type paddle apparatus is used. About 5ml of the 
dissolution medium was pipetted out for every 15, 30, 60, 120, 240, 480, 960 mins 
and the volume was adjusted using by replacing with 5ml of 0.1N HCl or with pH 6.8 
phosphate buffer. The samples collected were analysed using UV spectrometer at 
275nm.  
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6. RESULTS AND DISCUSSION 
Preformulation studies: 
In preformulation studies drug characteristics was performed and results were complies with 
pharmacopoieal values 
A. Standard graph of Aceclofenac: the dissolution studies for the floating tablet have to 
be conducted in 0.1N HCl.  Hence, UV spectrum of aceclofenac in 0.1N HCl was 
recorded on Elico spectrophotometer. The spectrum has shown λmax of 275nm which 
is selected for the construction of standard graph of aceclofenac in 0.1N HCl. 
A plot of absorbance Vs concentration of aceclofenac in 0.1N HCl is found to be 
linear in the concentration range of 5-25µg/ml indicating a perfect relation between 
drug concentration and absorbance 
Table-6   Standard plot of Aceclofenac 
CONCENTRATION 
(µg/ml) 
ABSORBANCE 
5 0.065 
10 0.131 
 
15 0.192 
 
20 0.252 
 
25 0.321 
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Fig-19 Standard curve of aceclofenac  
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Fig 20 FTIR of Aceclofenac 
 
Fig 21 FTIR of Aceclofenac + Carbopol 940 
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Fig 22 FTIR of Aceclofenac + guar gum 
 
Fig 23 FTIR of Aceclofenac + HPMC 
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B. Evaluation of Floating Tablets 
It is always necessary that the dosage forms prepared have to be evaluated for their 
characteristic properties. Hence quality control tests of tablets are performed to assess 
various properties of tablets.                      
Table 7 Preformulation –Flow properties 
 Formulation  Angle of 
repose(θ) 
Bulk density 
(gm/cm3) 
Tapped density 
(gm/cm3) 
Hausner 
ratio 
(HR) 
AF1 28.1±0.01 0.57±0.01 0.71±0.04 1.24±0.01 
AF2 26.3±0.02 0.55±0.02 0.67±0.03 1.22±0.02 
AF3 27.6±0.03 0.55±0.01 0.70±0.01 1.27±0.03 
AF4 26.9±0.04 0.54±0.03 0.73±0.03 1.35±0.01 
AF5 26.9±0.05 0.53±0.04 0.67±0.03 1.26±0.02 
 
i. Weight variation: tablets exhibit variation due to improper filling of die cavity, 
uneven distribution of ingradients in the compression and variation in conmpressional 
pressure. 
The total weight of each formulation is not maintained constant but the weight 
variation is in the range of +/-5% w/w indicating good control of compression process 
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Table 8 Weight Variation for (AF1-AF5) 
S.NO FORMULATIONS WEIGHT VARIATION 
(mg) 
1 AF1 460±0.12 
2 AF2 462±0.34 
3 AF3 460±0.33 
4 AF4 460±0.33 
5 AF5 457±0.42 
 
ii. Friability: It is a measure of tablet strength. It is related to tablets ability to withstand 
both shock and abrasion without crumbing during the handling of manufacture, 
jacking, shipment and consumer use. 
         The friability was determined as the percentage loss in the weight of the tablets. A 
loss of less than 0.5 to 1% in weight is generally considered acceptable. 
Table 9 Percentage Friability for (AF1-AF5) 
S.NO FORMULATIONS FRIABILITY (%) 
1 AF1 0.25±0.01 
2 AF2 0.30±0.06 
3 AF3 0.45±0.04 
4 AF4 0.55±0.02 
5 AF5 0.21±0.03 
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iii. Hardness:  Hardness was measured using Pfizer hardness tester which measure the 
pressure required to break the diametrical placed tablets by the pressure with coiled 
spring. 
Table 10 Hardness for (AF1-AF5) 
S.NO FORMULATION HARDNESS 
1 AF1 4.5±0.2 
2 AF2 5.0±0.1 
3 AF3 4.5±0.12 
4 AF4 5.0±0.16 
5 AF5 5.5±0.09 
 
iv. Thickness: the thickness of the tablet is measured by using screw gauge. It gives the 
changes in weight variation of the tablet 
 
         Table -11 Thickness for (AF1-AF5) 
S.NO AF1 THICKNESS (mm) 
1 AF2 3.0±0.01 
2 AF3 2.9±0.05 
3 AF4 3.1±0.02 
4 AF5 3.2±0.02 
5 AF1 3.0±0.02 
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v. Floating lag time: the floating lag time is determined in order to assess the time taken 
by the dosage to float on the top of the dissolution medium, after placing the dosage 
form in the medium 
     Table 12 Floating lag time (sec) & Floating time  (hrs) for (AF1-AF5) 
 
vi. Drug content: 
Table 13 % Drug content for (AF1-AF5) 
S.No Formulation Drug content (%) 
1 AF1 98.5±0.1 
2 AF2 97.2±0.2 
3 AF3 98.1±0.6 
4 AF4 97.5±0.5 
5 AF5 98.3±0.1 
 
C. Dissolution studies: freshly prepared dissolution medium i.e 900ml 0.1N HCl in each 
dissolution vessel of dissolution paddle apparatus maintained at temperature 37+/- 
S.NO FORMULATION FLOATING LAG TIME (sec) FLOATING 
TIME (hrs) 
1 AF1 30 8  
2 AF2 120 9 
3 AF3 40 6 
4 AF4 75 6 
5 AF5 240 9 
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0.50C and rotated at 75 rpm. The tablets of aceclofenac were placed in dissolution 
medium. About 5ml of the dissolution medium was pipetted out for every 15, 30, 60, 
120, 240, 480, 960 min and the volume was adjusted using by replacing with 5ml of 
0.1N HCl. The above samples i.e 5ml (7 samples ) were collected in a volumetric 
flask and      make up   the volume to 10ml with 0.1N HCl. Finally the absorbance of 
the solution was taken using UV spectrometer at 275 nm. 
 
Table-14 Percentage Cumulative Drug Release 
TIME(h) % CUMULATIVE DRUG RELEASE 
Formulations AF1 AF2 AF3 AF4 AF5 
0 0 0 0 0 0 
1  20.3 12.8 16.9 17.9 13.6 
2  43.5 13.2 24.3 22.7 21.6 
4  59.1 28.9 32.5 36.3 33.6 
8  72.6 37.1 46.3 44.3 44.8 
12  80.4 46.5 59.7 56.6 62.3 
16 85.2 56.9 72.2 72.6 71.3 
20 95.3 62.2 86.9 82.1 76.8 
24 98.4 72.2 88.3 84.1 80.3 
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Fig 23 Cumulative % Drug Release curve 
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7. SUMMARY AND CONCLUSION 
 
Floating drug delivery systems prolongs the gastric residence time which in turn 
produces increased drug bioavailability. Due to its less density than the aqueous medium, it 
floats in the gastric fluid. These drug delivery systems are suitable in the stomach or in upper 
small intestine due to its narrow absorption window.  
Inflammation is part of the complex biological response of vascular tissues to harmful 
stimuli, such as pathogens, damaged cells, or irritants. Inflammation is a protective attempt 
by the organism to remove the injurious stimuli and to initiate the healing process. 
In this present project, aceclofenac was used as a model drug for the floating tablets. 
Aceclofenac is used in the treatment of inflammation, and it is used as analgesic, anti-arthritic 
agent also.  
Aceclofenac decrease pain and suppresses the disease severity and improves the 
therapeutic efficiency. It reduces pain in joint inflammation, pain intensity and the duration of 
morning stiffness in patients with rheumatoid arthritis. The duration of morning stiffness and 
pain intensity are reduced and spinal mobility improved, by aceclofenac in patients with 
ankylosing spondylitis. 
Floating tablets of aceclofenac were developed to prolong gastric residence time and 
increase its bioavailability.  
Floating tablets of aceclofenac were prepared using individual and combination of 
polymers. The polymers HPMC, Carbopol 940 and guar gum were used in different ratios. 
Totally five formulations (AF1-AF5) were designed and formulated. The flow properties bulk 
density, tap density, angle of repose for the granules was determined and the results were 
found to be within the limit for all the formulations. The aceclofenac floating tablets were 
prepared by direct compression method. The direct compression method is easy, simple and 
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time consuming. These formulations (AF1-AF5) were evaluated for various tests like weight 
variation, content uniformity, friability, hardness and dissolution studies. 
  The hardness and friability of the tablets were within the limits for all the 
formulations. 
The weight variation of the tablets was found to be within the limits.  
The content uniformities of the prepared tablets were found to be within the limits. 
The floating lag time for the prepared formulation was ideal for the floating drug delivery 
systems. 
 The percentage drug release of the formulations AF1, AF2, AF3, AF4 and AF5 was 
98.4, 72.2, 88.3, 84.1 and 80.3 up to 24 hour 
 The formulation (AF1) prepared with HPMC showed good floating time and 
formulation (AF2) with carbopol 940 showed good floating time i.e 8 hours.  
The formulation (AF1) with hydroxypropylmethyl cellulose was found to be best 
formulation with floating time of 8 hrs and drug release of about 98.4% at the end of 24th 
hour. 
This present research work focuses on the floating tablets of aceclofenac, and 
succeeded in the formulation. But still research to be continued to in vivo studies to prove the 
effectiveness of the prepared aceclofenac floating tablets. 
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